Improved detection of XXXX with fluorescence immunocytochemistry (uCyt+ assay) and urinary cytology: results of a French Prospective Multicenter Study.

@entity1 @entity150 @entity189 @entity5
The aim of the study was to assess the sensitivity and specificity of fluorescence immunocytochemistry (uCyt+ assay) as combined with urinary cytology for detection of primary and recurrent @entity189 . We analyzed 694 urinary samples from 236 new symptomatic @entity1 and 458 @entity1 followed after transurethral resection (TUR) for @entity150 . Lesions suspicious for @entity5 at cystoscopy were sampled by biopsies or TUR. Sensitivity and specificity of tests were calculated using cystoscopy and histopathology, whether or not combined as gold standards. In new symptomatic @entity1 , sensitivity of uCyt+ was 40%, 88.2%, and 76.7%, whereas that of urinary cytology was 30%, 70.6%, and 83.3%, respectively, in G1, G2, and G3 @entity5 . In follow-up cases, sensitivity of uCyt+ was 61.9%, 66.7%, and 76.9%, whereas that of urinary cytology was 38.1%, 58.3%, and 64.1%, respectively, in G1, G2, and G3 @entity5 . The combination of uCyt+ and urinary cytology significantly increased mean sensitivity in newly diagnosed cases (86.4% versus 71.2% with urinary cytology only, p < 0.05), as well as in @entity1 followed after TUR (79.3% versus 55.2%, p < 0.001). Specificity of uCyt+ and urinary cytology was identical in new @entity1 (83.3%) and was 81.9% and 86.2%, respectively, in @entity1 followed after TUR. In @entity1 with negative cystoscopy, positive uCyt+ tests had a strong predictive value for @entity5 recurrence at 1 year (47.0% versus 11.9% in @entity1 with negative assay, p < 0.01). We conclude that combining uCyt+ with urinary cytology improves the detection of @entity189 as well in @entity1 with symptoms suggesting @entity150 as in those followed after treatment.
